Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators
about
The role of urotensin II in cardiovascular and renal physiology and diseasesUrotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenolThe G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signallingGSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivoHemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistulaDown-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticityViral-mediated gene delivery for cell-based assays in drug discovery.Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF miceActivation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin IIThe peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systemsPotential Clinical Implications of the Urotensin II Receptor Antagonists.Effects of urotensin-II on cytokines in early acute liver failure in mice.The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells.The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophyUrotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S PathwayUrotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway.Autocrine Human Urotensin II Enhances Macrophage-Derived Foam Cell Formation in Transgenic Rabbits.Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice.A closer look at the role of urotensin II in the metabolic syndrome.The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats.Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium.PPAR-gamma expression in animals subjected to volume overload and chronic Urotensin II administration.IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure.Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells.Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells.Urotensin II is raised in children with congenital heart disease.Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats.Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats.Early growth response 1 is an early signal inducing Cav3.2 T-type calcium channels during cardiac hypertrophy.The Role of Human Urotensin-II in Patients with Hypertrophic Cardiomyopathy.Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts.1,3,4-Thiadiazol-2-amine Derivatives as Urotensin-II Receptor (UT) AntagonistsThe Melanocortin MC5R as a New Target for Treatment of High Glucose-Induced Hypertrophy of the Cardiac H9c2 Cells
P2860
Q24675590-1285A016-A7DD-4A74-B4B6-10F3EEB52629Q28573864-E7F32EFA-A8C4-40EF-8519-B61F351F656AQ33599835-E090850F-BBFF-4746-AF4E-A835AC3F08F9Q33991646-DBC38480-F735-4A58-9A84-E964B2EB6B7DQ34233981-C078ED74-9749-422B-9BA9-DEEEF0314F7AQ34248766-5A94CA1D-1E4F-47EB-93BF-DDF7DCD1ADB5Q34260110-7770A1F4-20AC-4E9E-93FE-65A01102AA61Q34620084-ED4958EA-B5A3-419C-8F60-D9A6E10F4E54Q34765931-A5A66C14-6CFF-44C4-BCE5-60F19D937F60Q35048941-362C9936-253F-45E3-9606-35415A63ED24Q35100902-A18F4EB0-7716-4D62-A5EC-2B362ED18FF2Q35128456-CDC8E6E2-01B4-4602-AF38-4B01ECAF4351Q35188586-1917D222-7578-4D6F-A31A-65EC7617C5F5Q35214202-3BD46F40-50D6-4A09-BFF0-02F9E0565B32Q35538538-84A132F6-9763-4F5F-ABEB-FF29C0F9BFC8Q35813861-A4B2A7C4-44A8-406F-97BF-CDDBA474B811Q35895186-BD9B56AD-D624-4229-8ECD-3189CF66C816Q36320177-31962EAA-0E51-47F8-B818-D5B9291621B3Q36424203-1DE0FBF3-4356-47FC-8CC0-7E56F7D2E4F1Q36492706-B70C721C-1CA4-4B7F-98B2-7720CDA6BB4EQ36986355-7B6CC468-9661-4836-B4B1-CA92ECC86E76Q37082781-E9EE6208-25BB-49BA-A148-65F9B1AC5BD2Q37394539-269BCEF4-7554-4255-850C-27F658CFB78EQ37422701-15961E5F-5788-4332-9D1F-2F65E33DF71BQ37580160-8ECFD716-2262-4398-8944-C20FA6BF0947Q39835304-FAF05E0C-A159-44D0-9DE5-343F8E02081BQ40430686-6F934A68-F54B-4230-9017-F5E843E6AEA2Q42275443-C24DE154-3FEE-46BA-921D-1D1B36666C72Q42833174-BA52CB2B-5C21-438D-8550-EA958EB42245Q42876530-B779B167-17D4-4A79-9012-269A7119973CQ43268409-CE5CCC69-7B3C-4589-B715-6C2A91BCA14CQ43471762-077EEF9A-2D17-4262-8AC4-1FA6BA901436Q47706645-E87D58F0-AE3C-4E1B-8E4A-1C55782A0A9FQ54643074-0633F60F-613D-48AE-8896-355EE93986B9Q57771763-48D8AD9E-D3C5-4B70-B2D2-F50E60A7685BQ58707465-A4B649A0-BB31-4092-8355-85205B2A6ACD
P2860
Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators
description
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
im Oktober 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2004/10/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/10/01)
@nl
наукова стаття, опублікована в жовтні 2004
@uk
مقالة علمية (نشرت في أكتوبر 2004)
@ar
name
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@ast
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@en
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@nl
type
label
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@ast
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@en
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@nl
prefLabel
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@ast
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@en
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@nl
P2093
P2860
P3181
P1476
Urotensin-II-mediated cardiomy ...... role of inflammatory mediators
@en
P2093
Christopher L. Herold
Diane Naselsky
Douglas G. Johns
Klaudia Steplewski
Kristeen Maniscalco
Lea Sarov-Blat
Nambi Aiyar
Stephen A. Douglas
Zhaohui Ao
P2860
P2888
P304
P3181
P356
10.1007/S00210-004-0980-Z
P577
2004-10-01T00:00:00Z
P6179
1029753535